Page last updated: 2024-11-06
neoquassin
Description
Neoquassin is a quassinoid compound with a complex structure and potent biological activity. It is isolated from the bark of the Quassia amara tree and has shown promising anticancer, antimalarial, and antiviral properties. Neoquassin is a complex molecule with a highly oxygenated structure. Its synthesis is challenging and has been achieved through various approaches, including multi-step reactions and biomimetic methods. Research on neoquassin focuses on understanding its mechanism of action and exploring its potential as a therapeutic agent. Its ability to inhibit the growth of cancer cells and its antimalarial activity have made it a target for drug development. Neoquassin also exhibits antiviral properties against various viruses, including HIV and influenza. Its potential for treating infectious diseases and cancers makes it a valuable subject of ongoing research. '
neoquassin: a CYP1A1 inhibitor isolated from Picrasma excelsa; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Picrasma | genus | A plant genus of the family SIMAROUBACEAE. Members contain javanicins, picrasinoside and other quassinoids.[MeSH] | Simaroubaceae | A plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida. Leaves are alternate and compound. Most have small flowers, bitter bark, and fleshy fruits that are sometimes winged. Members contain QUASSINS.[MeSH] |
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 72964 |
| CHEMBL ID | 517757 |
| CHEBI ID | 7512 |
| SCHEMBL ID | 1276842 |
| MeSH ID | M0534146 |
Synonyms (17)
| Synonym |
|---|
| simalikahemiacetal a |
| picrasa-2,12-diene-1,11-dione, 16-hydroxy-2,12-dimethoxy- |
| hydroxy-dimethoxy-tetramethyl-[?]dione |
| C08771 |
| neoquassin |
| LMPR0106110001 |
| CHEMBL517757 |
| chebi:7512 , |
| nsc 139168 |
| unii-9mq0p9426v |
| 9mq0p9426v , |
| SCHEMBL1276842 |
| neoquassin [mi] |
| Q27107517 |
| HY-122932 |
| E88610 |
| CS-0090488 |
Drug Classes (1)
| Class | Description |
|---|
| triterpenoid | Any terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID356616 | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected erythrocytes by [3H]hypoxanthine uptake | 2003 | Journal of natural products, Nov, Volume: 66, Issue:11
| Enhancement of the antiplasmodial activity of quassin by transformation into a gamma-lactone. |
| AID356617 | Cytotoxicity against human KB cells by microplate method | 2003 | Journal of natural products, Nov, Volume: 66, Issue:11
| Enhancement of the antiplasmodial activity of quassin by transformation into a gamma-lactone. |
| AID356618 | Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum K1 | 2003 | Journal of natural products, Nov, Volume: 66, Issue:11
| Enhancement of the antiplasmodial activity of quassin by transformation into a gamma-lactone. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.14
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 20.14 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.30 (4.65) | | Search Engine Demand Index | 15.26 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |